Brian Moran, MD, founder and principal of the Chicago Prostate Cancer Center (CPCC) presented the results of his two-year investigation into key characteristics of Cesium-131 at the 28th American Brachytherapy Society Annual Meeting, held in Chicago April 29th through May 1, 2007. Dr. Moran concluded that the medical isotope is effective and well-tolerated in its use to kill cancer cells in low dose (LDR) brachytherapy therapy for the treatment of prostate cancer.
CHICAGO (BusinessWire EON) May 1, 2007 --
Brian Moran, MD, founder and principal of the Chicago
Prostate Cancer Center (CPCC) presented the results of his two-year
investigation into key characteristics of Cesium-131
at the 28th American Brachytherapy Society Annual Meeting, held in
Chicago April 29th through May 1, 2007. Dr. Moran concluded that the
medical isotope is effective and well-tolerated in its use to kill
cancer cells in low dose (LDR) brachytherapy
therapy for the treatment of prostate
cancer.
“Analysis of the patients we have treated
using Cesium-131 strongly suggest they experience more limited side
effects that are also shorter in duration when compared to other
isotopes,” stated Dr. Moran. “We
are a center of excellence, and we are constantly pursuing new ideas and
technologies. Cesium-131 has adapted well to our philosophy.”
The study was one of several scientific presentations at the meeting
that detailed new information about the safety and efficacy of
Cesium-131, a proprietary product of IsoRay Medical™.
It is a wholly owned subsidiary of a public company, IsoRay,
Inc. (“IsoRay”)
(AMEX:ISR), based in Richland, WA. Cesium-131
is the newest isotope used in brachytherapy for the treatment of
prostate cancer, and the first breakthrough in more than 20 years.
Dr. Moran presented his study, called Cesium-131 Prostate
Brachytherapy: An Early Experience, to the physicians, physicists
and others interested in brachytherapy who gathered from across the
country to attend the meeting held at the Sheraton Chicago Hotel and
Towers.
Study parameters and conclusion
Dr. Moran's study investigated the prostate specific antigen (PSA)
response and acute side effects of patients undergoing low dose-rate,
ultrasound-guided, transperineal prostate brachytherapy (PB) with
Cesium-131 seeds. It was conducted from November 2004 to November 2006
with 104 patients with a median age of 61.3 years (range 44-77 years).
The study concluded that “PB with Cesium-131
is effective and well-tolerated; both PSA response and the acute
morbidity profile are very encouraging.”
Change in PSA is a key measure that physicians use to access response to
treatment for prostate cancer.
“The findings of this important study
correlate with the experiences of many Cesium-131 patients,”
said IsoRay Medical Director Dr. Steven Kurtzman and a principal with
the San Francisco Bay area Silicon Valley Urology Center. “They
are able to return to normal activities quickly, and the lengths of
normal side effects are minimized.”
CPCC is one of the few centers in the United States dedicated solely to
the treatment of prostate cancer using brachytherapy; and one of the
busiest implant centers in the country with over 8,000 patient implants
in nine years.
Founded in 1997, CPCC is a 35,000-square-foot, state-of-the-art facility
located at 815 Pasquinelli Drive in Westmont, Illinois, a suburb of
Chicago. For more information, visit www.prostateimplant.com.
Cesium-131 offers patients unique advantages over
other medical isotopes
Increasingly, prostate cancer patients and their doctors who decide on
seed brachytherapy choose Cesium-131 treatment because of its
significant advantages over Palladium-103 and Iodine-125, two other
isotopes currently in use. These advantages include:
Higher Energy
Cesium-131 has a higher average energy than any other commonly used
prostate brachytherapy isotope on the market. Energy is a key factor in
how uniformly the radiation dose can be delivered throughout the
prostate. This is known as homogeneity. Early studies demonstrate
Cesium-131 implants are able to deliver the required dose while
maintaining good homogeneity across the gland itself and potentially
reducing unnecessary dose to critical structures such as the urethra and
rectum. [1]
Shorter Half-Life
Cesium-131 has the shortest half-life of any prostate brachytherapy
isotope at 9.7 days. Cesium-131 delivers 90% of the prescribed dose to
the prostate in just 33 days compared to 58 days for Palladium and 204
days for Iodine-125. The short half-life of Cs-131 reduces the duration
of time during which the prostate receives the irritating effects of the
radiation. Early studies demonstrate Cesium-131 is well tolerated with
minimal to moderate urinary symptoms that resolve relatively rapidly,
within approximately 4-8 weeks. [1]
Higher Biologically Effective Dose
Another benefit to the short half-life of Cesium-131 is what is known as
the “biological effective dose”
or BED. BED is a way for health care providers to predict how an isotope
will perform against slow versus fast growing tumors. Studies have shown
Cesium-131 is able to deliver a higher BED across a wide range of tumor
types than either Iodine-125 or Palladium-103. Although prostate cancer
is typically viewed as a slow growing cancer it can present with
aggressive features. Cesium-131's higher BED may be particularly
beneficial in such situations. [2]
For more information on the Cesium-131 cancer treatment breakthrough,
visit www.cesium131.com
Medicare / Medicaid
Medicare and Medicaid have established a specific reimbursement code for
Cesium-131, and most insurance companies also cover low-dose (LDR) seed
brachytherapy.
FOOTNOTES:
[1] Prestidge
B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent
Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology
Biol. Phys. 2005: 63 (1) 5336-5337.
[2] Armpilia CI,
Dale RG, Coles IP et al. The Determination of Radiobiologically
Optimized Half-lives for Radionuclides Used in Permanent Brachytherapy
Implants. Int. J. Radiation Oncology Biol. Phys. 2003; 55 (2):
378-385.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical™,
Inc., is the sole producer of the Cesium-131 brachytherapy seed, used to
treat prostate and other cancers. The Cesium-131 seed offers a
significantly shorter half-life than the two other isotopes commonly
used for brachytherapy, which results in a substantially faster delivery
of therapeutic radiation, lower probability of cancer cell survival and
reduction of the longevity of common brachytherapy side effects. IsoRay
is based in Richland, Washington. More information is available about
IsoRay at www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations,
including: the advantages of our Cesium-131 seed, future production
capabilities, development of protocols for the use of our Cesium-131
seed to treat cancers other than prostate cancer, the level of market
share our seed may attain, and all other statements in this release,
other than historical facts, are forward-looking statements. It is
important to note that actual results and ultimate corporate actions
could differ materially from those in such forward-looking statements
based on such factors as physician acceptance, training and use of our
products, our ability to successfully manufacture, market and sell our
products, our ability to manufacture our products in sufficient
quantities to meet demand within required delivery time periods while
meeting our quality control standards, and our ability to enforce our
intellectual property rights, and other risks detailed from time to time
in IsoRay's reports filed with the SEC.
Optimized by Newsforce
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1QaWdnLVpldGEtUHJvZi1NYWduLVplcm8=
|
